<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02454387</url>
  </required_header>
  <id_info>
    <org_study_id>ONO-4474-01</org_study_id>
    <nct_id>NCT02454387</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacology of ONO-4474 in Healthy Volunteers</brief_title>
  <official_title>A Double-blind, Single and Multiple Ascending Dose, Randomised, Placebo-controlled Study, in Healthy Adult and Elderly Subjects Exploring Safety, Tolerability, Pharmacokinetics of ONO-4474 and Pharmacology of ONO-4474 in NGF-hyperalgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ono Pharmaceutical Co. Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacology of
      ONO-4474 in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Double-blind, Multi-centre, Single Dose, Single and Multiple Ascending Dose, Four-part,
      Randomised, Placebo-controlled Study in Healthy Adult and Elderly Subjects Exploring the
      Safety, Tolerability, Pharmacokinetics of ONO-4474 in Fed and Fasted Conditions, and
      Pharmacology of ONO-4474 in NGF-hyperalgesia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of ONO-4474 across ascending single and multiple doses using number of adverse events</measure>
    <time_frame>Up to Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration of ONO-4474 (Cmax)</measure>
    <time_frame>Day 1 and at Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ONO-4474 Plasma Area Under the Curve from Time Zero to 24 hour after dosing (AUC24)</measure>
    <time_frame>Day 1 and at Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma concentration (Tmax) of ONO-4474</measure>
    <time_frame>Day 1 and at Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay half life (T1/2) of ONO-4474</measure>
    <time_frame>Day 1 and at Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part C only - Evaluation of ONO-4474 vs. placebo on walking soreness using a Likert scale</measure>
    <time_frame>3hr and 24hr after NGF injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part C only: Assessment of pharmacology of ONO-4474 using change in pressure pain threshold after NGF injection.</measure>
    <time_frame>3hr and 24hr after NGF injection</time_frame>
    <description>Pressure algometry at site of NGF injection (anterior tibialis)</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">141</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Experimental: ONO-4474 Part A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: ONO-4474 Placebo Part A1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: ONO-4474 Part A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single doses (2 periods) of ONO-4474 or placebo, randomized 3 active: 1 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: ONO-4474 Placebo Part A2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single doses (2 periods) of ONO-4474 or placebo, randomized 3 active: 1 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: ONO-4474 Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple ascending doses of ONO-4474 or placebo, randomized 3 active: 1 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: ONO-4474 Placebo Part B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple ascending doses of ONO-4474 or placebo, randomized 3 active: 1 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: ONO-4474 Part C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGF hyperalgesia and single or multiple doses of ONO-4474, randomized 1 active: 1 placebo in cross over design</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: ONO-4474 Placebo Part C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NGF hyperalgesia and single or multiple doses of ONO-4474, randomized 1 active: 1 placebo in cross over design</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: ONO-4474 Part D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: ONO-4474 Placebo Part D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-4474 Part A1</intervention_name>
    <description>Healthy volunteers</description>
    <arm_group_label>Experimental: ONO-4474 Part A1</arm_group_label>
    <other_name>ONO-4474</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Part A1</intervention_name>
    <description>Healthy volunteers</description>
    <arm_group_label>Experimental: ONO-4474 Placebo Part A1</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-4474 Part A2</intervention_name>
    <description>Healthy volunteers</description>
    <arm_group_label>Experimental: ONO-4474 Part A2</arm_group_label>
    <other_name>ONO-4474</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Part A2</intervention_name>
    <description>Healthy volunteers</description>
    <arm_group_label>Experimental: ONO-4474 Placebo Part A2</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-4474 Part B</intervention_name>
    <description>Healthy volunteers</description>
    <arm_group_label>Experimental: ONO-4474 Part B</arm_group_label>
    <other_name>ONO-4474</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Part B</intervention_name>
    <description>Healthy volunteers</description>
    <arm_group_label>Experimental: ONO-4474 Placebo Part B</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-4474 Part C</intervention_name>
    <description>Healthy volunteers</description>
    <arm_group_label>Experimental: ONO-4474 Part C</arm_group_label>
    <other_name>ONO-4474</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Part C</intervention_name>
    <description>Healthy volunteers</description>
    <arm_group_label>Experimental: ONO-4474 Placebo Part C</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-4474 Part D</intervention_name>
    <description>Healthy volunteers</description>
    <arm_group_label>Experimental: ONO-4474 Part D</arm_group_label>
    <other_name>ONO-4474</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Part D</intervention_name>
    <description>Healthy volunteers</description>
    <arm_group_label>Experimental: ONO-4474 Placebo Part D</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male subjects aged 18-55 years inclusive (Parts A and C); healthy male and
             female subjects aged 18-55 years inclusive (Part B); healthy male and female subjects
             aged 65 and over (Part D)

          2. Subjects with a body mass index of 18.0-30.0 kg/m2 inclusive

        Exclusion Criteria:

          1. Subjects who have a clinically relevant history or presence of any clinically
             significant disease or disorder

          2. Current smokers or those that have smoked or used nicotine products within 6 months of
             the Screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Drug Development Division</last_name>
    <role>Study Director</role>
    <affiliation>Ono Pharmaceutical Co. Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aalborg Clinical Site</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham Clinical SIte</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2015</study_first_submitted>
  <study_first_submitted_qc>May 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2015</study_first_posted>
  <last_update_submitted>June 29, 2016</last_update_submitted>
  <last_update_submitted_qc>June 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

